Cholera remains a major global public health challenge, with an estimated 1.3 to 4 million cases and tens of thousands of ...
The "In Situ Hybridization Market Report by Product, Technique, Application, End User, Countries and Company Analysis ...
1 Department of Clinical Laboratory, The First Hospital of Jilin University, Changchun, China 2 College of Medical Technology, Beihua University, Jilin, China Human papillomavirus (HPV) infection ...
CRISPR has the power to correct genetic mutations, but current delivery methods are either unsafe or inefficient, keeping the technology from reaching its full medical potential. With the power to ...
San Diego CDMO TriLink BioTechnologies is reducing its headcount while its parent company, Maravai LifeSciences, moves forward with a broader restructuring plan. TriLink is letting go of 69 employees ...
Graphical representation of the most common gynecological diseases covered in the present study. The figure was developed by the authors using Biorender software. BV is characterized by an imbalance ...
Section 1. Purpose. Dangerous gain-of-function research on biological agents and pathogens has the potential to significantly endanger the lives of American citizens. If left unrestricted, its effects ...
Turku PET Centre, University of Turku and Turku University Hospital, Turku FI-20520, Finland Department of Chemistry, University of Turku, Turku FI-20500, Finland Turku PET Centre, University of Turku ...
To develop RNA medicines targeting a proprietary bundle of tumor antigens, Epitopea is tapping nucleic acid delivery specialist Genevant Sciences in a deal worth up to $123.5 million. Genevant can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback